• Journal Article

Validation of the SF-36 in patients with endometriosis

Citation

Stull, D., Wasiak, R., Kreif, N., Raluy, M., Colligs, A., Seitz, C., & Gerlinger, C. (2014). Validation of the SF-36 in patients with endometriosis. Quality of Life Research, 23(1), 103-117. DOI: 10.1007/s11136-013-0442-5

Abstract

OBJECTIVES: Endometriosis presents with significant pain as the most common symptom. Generic health measures can allow comparisons across diseases or populations. However, the Medical Outcomes Study Short Form 36 (SF-36) has not been validated for this disease. The goal of this study was to validate the SF-36 (version 2) for endometriosis. METHODS: Using data from two clinical trials (N = 252 and 198) of treatment for endometriosis, a full complement of psychometric analyses was performed. Additional instruments included a pain visual analog scale (VAS); a physician-completed questionnaire based on patient interview (modified Biberoglu and Behrman-B&B); clinical global impression of change (CGI-C); and patient satisfaction with treatment. RESULTS: Bodily pain (BP) and the Physical Component Summary Score (PCS) were correlated with the pain VAS at baseline and over time and the B&B at baseline and end of study. In addition, those who had the greatest change in BP and PCS also reported the greatest change on CGI-C and patient satisfaction with treatment. Other subscales showed smaller, but significant, correlations with change in the pain VAS, CGI-C, and patient satisfaction with treatment. CONCLUSIONS: The SF-36-particularly BP and the PCS-appears to be a valid and responsive measure for endometriosis and its treatment